Alectinib has become the mainstay of treatment in ALK-positive NSCLC due to its long-term efficacy, high selectivity, and CNS-active ALK-inhibiting activity.[11,13-15] Several clinical trials have demonstrated its efficacy against various ALK variants. This evidence concerns the gene ALK and non-small cell lung carcinoma.